Transcatheter aortic valve implantation in failed bioprosthetic surgical valves.

By D. Dvir, J. Webb, S. Bleiziffer, M. Pasic, R. Waksman, S. Kodali, M. Barbanti, A. Latib, U. Schaefer, J. Rodés‐Cabau and 28 more. Journal of the American Medical Association (JAMA), 2014

853 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/0e7d3863fce543bf88fa271001c726a5e7174e8f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “B-NR For severely symptomatic patients with biopro aortic valve stenosis judged by the heart team high or prohibitive risk of reoperation, and in improvement in hemodynamics is anticipated, transcatheter valve-in-valve procedure is reas (154,247,248).”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “B-NR For severely symptomatic patients with biopro aortic valve stenosis judged by the heart team high or prohibitive risk of reoperation, and in improvement in hemodynamics is anticipated, transcatheter valve-in-valve procedure is reas (154,247,248).”